Elahere

Elahere is indicated as a treatment for adult patients with FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. These patients should havereceived one to three prior systemic treatment regimens.

The selection of patients for this therapy should be based on an FDA-approved test. Accelerated approval for this indication is based on tumor response rate and durability ofresponse. Continued approval may be contingent upon verification and description of clinicalbenefit in a confirmatory trial.

Submit an Enquiry

Category: Innovator Products Brand: ImmunoGen

Description
Reviews (0)

Description

Recommended Dosage:

The recommended dose of Elahere is 6 mg/kg adjusted ideal body weight, given as an intravenous infusion every 3 weeks until disease progression or unacceptable toxicity.

Patients should receive premedication with a corticosteroid, antihistamine, and antipyretic. Additionally, premedication with an antiemetic, ophthalmic topical steroids, and lubricating eyedrops is recommended.

Elahere should be administered as an intravenous infusion after dilution in 5% Dextrose Injection,
USP, as it is not compatible with normal saline.